Antibe Therapeutics רווח 2025

מה עושה Antibe Therapeutics?

Antibe Therapeutics Inc is a biopharmaceutical company specializing in the development of novel treatment methods for inflammation and pain. The Canadian company was founded in 2009 and is headquartered in Toronto, Ontario. Antibe Therapeutics has made a name for itself in the pharmaceutical industry through its innovative technologies and compounds. The business model of Antibe Therapeutics is based on the discovery and development of new compounds based on non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are among the most commonly used medications for the treatment of inflammation and pain. However, Antibe Therapeutics has developed a promising method to optimize the compounds of NSAIDs and minimize their side effects. The company is divided into three divisions to organize its products and services. The first division is the analgesic pipeline, which focuses on the research and development of neuromodulation programs for the treatment of pain and inflammation. Antibe Therapeutics' neuromodulation technology aims to target specific receptor systems to treat inflammation and pain specifically. The second division is the GI Safety Inhibition Concept, which offers a novel anti-inflammatory technology for the treatment of pain and inflammation with improved gastrointestinal tolerability. This technology aims to minimize the side effects of NSAIDs, particularly in the gastrointestinal system. The third division is the clinical development, which conducts clinical trials for new medications. Antibe Therapeutics has a number of drugs in clinical development, including ATB-346, which is considered a novel anti-inflammatory and pain-reducing medication for patients with arthritis and other inflammatory conditions. Another important product of Antibe Therapeutics is the fully synthesized hydroxyliminodiazole molecule (ATB-352), which is used for the treatment of neuropathic pain. The company believes that ATB-352 offers promising benefits over conventional pain medications and represents an effective treatment option for patients with chronic pain. Antibe Therapeutics has established several partnerships with major pharmaceutical companies in the past to advance the development and commercialization of its products. In 2020, Antibe Therapeutics entered into an agreement with Nuance Pharma, a leading Chinese company in the development and commercialization of anesthetics, to market ATB-346 in China and adjacent areas. This partnership provides Antibe Therapeutics with access to the rapidly growing markets in Asia and also strengthens its position as a global company. Overall, Antibe Therapeutics has found a valuable place in the pharmaceutical industry through its innovation and ability to focus on the areas of inflammation and pain. With a strong pipeline and a variety of promising product candidates, Antibe Therapeutics believes it is able to improve the lives of millions of people worldwide by providing safer and more effective treatment methods for inflammation and pain. Antibe Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.